ArticleThe American journal of case reports2026
An Integrated Approach to MSI-High Colorectal Cancer Therapy in a Young Patient: A Clinical Case.
Article in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Colorectal cancer (CRC) is extremely rare in adolescents and often presents with advanced disease because of nonspecific symptoms. Deficient mismatch repair (dMMR) and microsatellite instability-high (MSI-H) are important biomarkers that influence prognosis, treatment selection, and the need for genetic evaluation. We report the case of an adolescent with MSI-H-associated CRC presenting with acute intestinal obstruction. CASE REPORT A 16-year-old male initially underwent appendectomy for presumed acute appendicitis. Persistent postoperative bowel obstruction prompted computed tomography (CT), revealing a descending colon tumor requiring emergency Hartmann's procedure. Histopathology demonstrated mucinous adenocarcinoma, pT4N0M0, with vascular invasion. Immunohistochemistry showed loss of MSH2/MSH6 expression with retained MLH1/PMS2, indicating dMMR and findings highly suggestive of Lynch syndrome, although germline testing was unavailable. Molecular analysis identified a KRAS mutation without NRAS alterations. Given his multiple high-risk features, including T4 disease, bowel obstruction, vascular invasion, mucinous histology, and very young age, he received 12 cycles of adjuvant FOLFOX chemotherapy. Treatment was well tolerated, and he remains disease-free more than 5 years after completion of therapy. CONCLUSIONS This case highlights the diagnostic complexity of adolescent CRC and the need to consider colorectal malignancy in young patients with persistent or atypical abdominal symptoms. Routine MMR/MSI testing and comprehensive molecular profiling are essential in young-onset CRC to identify patients who may have hereditary cancer syndromes and require genetic counseling. Although limited to a single case, this report underscores the importance of multidisciplinary decision-making and individualized treatment based on clinicopathological and molecular characteristics, which may contribute to favorable long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.